(Research Article)

10

#### IJPSR (2023), Volume 14, Issue 8



INTERNATIONAL JOURNAL

Received on 05 December 2022; received in revised form, 15 February 2023; accepted 28 May 2023; published 01 August 2023

# FABRICATION AND CHARACTERIZATION OF DRUG-LOADED BIONANOFIBERS AS A PLATFORM FOR DRUG DELIVERY

S. N. Kharde<sup>\*</sup> and K. Saravanan

Bhagwant University, Ajmer - 305004, Rajasthan, India.

| Keywords:  | ABSTRACT: The Bionanofibers drug delivery systems can reduce toxicity,   |
|--|--|
| Bionanofibers, PVP, Macitentan,<br>Electrospining Method                       | improve therapeutic efficacy and increase patient compliance by delivering<br>drugs at a controlled rate to the site of action. The major aim in designing       |
| Correspondence to Author:<br>S. N. Kharde                                      | molecules with accurate doses at targeted sites. The present research work<br>developed Biopapofibers as a carrier for drug delivery. Because of the very        |
| Research Scholar,<br>Bhagwant University,<br>Ajmer - 305004, Rajasthan, India. | small nanoscale diameter and high surface area, significantly higher drug content<br>on he loaded in a very small volume. Pionenefibers were manufactured from   |
|  | Macitentan drug using PVP and Soybean PC by electrospinning. The obtained  |
| E-mail: sagarkharde1606@gmail.com  | and drug release behavior. FE-SEM images showed that the length of obtained  |
|  | bionanofibers is about 580nm to 1250nm in diameter. FTIR analysis shows no significant interaction between the drug and the polymer. The <i>in-vitro</i> release |
|  | study demonstrated that there is a controlled release pattern of drugs from  |
|  | bionanofibers.   |

**INTRODUCTION:** Nanofibers are known as fibers having diameters lower than 50-500 nanometers range. Nanofibers composed of biobased polymers potentially discover applications in the delivery of drugs, in medicine, in the protection of the environment, in agriculture, production, and processing of food, as well as other areas. It's having rare properties like high tensile strength, high surface area-to-volume ratio, high Young's modulus and lower coefficient of thermal expansion<sup>1</sup>. By releasing drugs to the local site at a controlled rate over time to achieve therapeutic effects, bionanofibers drug delivery systems are able to improve therapeutic efficacy, overcome toxicity and boost patient compliance.



Bionanofibers are an innovative new class of material with a wide range of uses, including medical, consumer, and industrial products as well as more complex ones like drug delivery systems, including colonic drug delivery, wound dressing, air and liquid filtration, composites for aerospace, battery separators and optical and chemical sensors <sup>2</sup>. The use of natural gum for pharmaceutical applications because of its properties such as biodegradable, biocompatible, easily available, nontoxic, economic and capable of chemical modifications mainly used in drug delivery as suspending agent, disintegrants, emulsifying agent, binder and release retardant <sup>3, 4</sup>.

The major aim in designing nanostructures as delivery systems are to deliver pharmacologically active molecules with accurate doses at targeted sites. Several studies have been conducted on the use of nanostructured biopolymers from renewable resources. Among that, the polysaccharides are the most abundant and renewable natural polymers. Cellulose is used as raw material in the production of bio-based nanofibers due to their ability to form transparent and strong fibers <sup>5, 6</sup>.

# **MATERIALS AND METHODS:**

**Material:** PVP with a mean molecular weight of 111.14 kD, Macitentan and all the solvents used for the electrospining were obtained from Sigma Aldrich. The solvents consisting of Methanol.

**Methods:** Prepare a polymer 1, 2, 3, 5 and 7% w/v solution of PVP and Soybean PC in Methanol (Solution A) by prespinning technique and In addition, a 3% (w/v) pre solution of the drug was prepared by dissolving the appropriate amount of pure Macitentan in methanol aqueous solutions before the electrospinning process at the same conditions. (Solution B) with stirring at ambient temperature and ambient humidity. The final spinning solution was obtained by mixing solutions A and B. In this study, electrospinning process was performed under ambient conditions. In order to provide the final spinning solution for the various

formulations, a certain concentration of the PVP solution was added to the drug solution Table 1. The final spinning solution was mixed and stirred by a magnetic stirrer with a fixed speed of 50 RPM for 30 min at room temperature and ambient humidity to obtain a homogeneous spinning solution. The solutions were degassed using an Ultra-Sonicator for 10 min. The spinning solutions were carefully loaded into a 10 ml syringe to avoid any air bubbles. The single-syringe infusion pump was used for injecting the spinning solution. The feed rate was fixed at 1.5 ml/ h. A high-voltage power DC supply was used as the positive electrode at a voltage of 14 kV. A metal collector was covered with aluminum foil and was applied as the grounded electrode. The Electrospun nanofibers were collected. The metal needle tip has 0.25 mm inner diameter. All samples were placed in silica gel beads in desiccators to facilitate the removal of moisture and residual organic solvents.

 TABLE 1: SOLUBILITY STUDIES OF PURE MACITENTAN, ELECTROSPUN NANOFIBER-BASED SOLID

 DISPERSIONS, AND THE PHYSICAL MIXTURE CONTAINING PVP

|            |                  |                                  | Theoretical d | rug content   |
|------------|------------------|----------------------------------|---------------|---------------|
| Batch      | Process          | Drug (w/v): Polymer (w/v) (%: %) | Amount(mg)    | Expressed (%) |
| Macitentan | -                | 3:0                              | 100           | 100           |
| M1         | Electrospinning  | 3:1                              | 75            | 100           |
| M2         | Electrospinning  | 3:2                              | 60            | 100           |
| M3         | Electrospinning  | 3:3                              | 50            | 100           |
| M4         | Electrospinning  | 3:5                              | 37.5          | 100           |
| M5         | Electrospinning  | 3:7                              | 30            | 100           |
| PM         | Physical mixture | 3:7                              | 30            | 100           |

In the next step, samples were collected for doing different tests. All samples were kept in plates with closed lids, out of sun radiation and at room temperature up to the next tests.

**Preparation of Physical Mixtures as Controls:** For the purpose of comparison, the drug and the polymer (%, w/w) was simply triturated to produce solid dispersions with the same content. In a porcelain mortar (drug and carrier were homogenized in a glass mortar by a spatula for 5 min). The mixtures were then sieved and stored in amber glass capped containers.

# **Evaluation of Macitentan Nanofibers:**

**Drug Entrapment Study:** Samples were centrifuged, the amount of drug contained in the clear supernatant was measured (w) using a UV spectrophotometer set to a wavelength of 280 nm.

For this, a drug calibration curve that is considered to be standard was plotted. The total amount of drug added during preparation was then deducted from the amount of drug in the supernatant (W). Effectively, (W-w) will give the amount of drug entrapped in the particles.

Then percentage entrapment of a drug was calculated according to Equation,

% Drug Entrapment = 
$$(W-w/W) \times 100$$

The efficiency study was determined by free drug content in the supernatant, which is obtained after centrifuging the solid lipid suspension at (15,000rpm for 20 min at 0°C using ultracentrifuge). The absorbance was measured at 280 nm by UV spectrophotometrically.

# **Characterization of Macitentan Nanofibers:**

Optical Microscopy: For assessing the spontaneous formation of self-assembled, 1.0 ml of distilled water was added to the pre-weighted sample (100 mg) of Macitentan -loaded NFs. The mixture was then gently and manually shaken for about 1–2 min at an ambient room temperature (22  $\pm$  2 °C) to obtain a homogenous dispersion. The dispersion was equilibrated for at least 10 min to form the self-deposition. The sample dilution was required for acquiring proper images. Then, the formation of the self-assembled imaged with an optical microscope.

**Fourier Transform Infrared Spectroscopy:** For verifying drug-polymer interactions of NFs, a Fourier transform infrared (FTIR) spectroscope and Single Reflection ATR crystal were used for the Macitentan, PC and PVP powders, as well as for the electrospun NFs. The analytical range was from  $550 \text{ cm}^{-1}$  to  $4000 \text{ cm}^{-1}$  and spectra (n = 3) were normalized and scaled.

**Scanning Electron Microscopy:** Different types of interactions, including secondary electrons, backscattered electrons, and distinctive X-rays, are produced when a precisely focused electron beam is traversed across the surface of the sample in scanning electron microscopy (SEM). Images of the sample are developed from these signals by detectors and projected onto a cathode ray tube screen. The elements present in the features can then be promptly determined using WDS. SEM is typically used to observe morphological, structural and surface properties of the nanofibers.

*In-vitro* **Drug Release:** Drug release from the electrospun nanofibers was carried out by placing a pre-defined size of nanofibers  $(1 \times 1 \text{ cm}^2)$  in 100 ml of Phosphate Buffer pH 6.8. The release

investigations were performed in a thermostatic shaking incubator at 37 °C and 100 rpm. The amount of drug present in the aliquots was determined at pre-defined intervals using a UV– visible spectrophotometer (Lab India UV-3000) at a  $\lambda_{max}$  of 280 nm, followed by the addition of fresh media to maintain sink conditions.

# **RESULT AND DISCUSSION:**

### **Evaluation of Macitentan Nanofibers:**

**Drug Entrapment Efficiency:** The Entrapment efficiency of Macitentan Nanofiber was analyzed by dialysis method. Increase the concentration of polymer, the entrapment efficiency Increases. From the above result **Table 2**, formulation M5 shows the highest percentage of entrapment efficiency of 95%, so formulation M5 was selected for further studies.

| TABLE  | 2:  | ENTRAPMENT  | EFFICIENCY | OF |
|--------|-----|-------------|------------|----|
| MACITE | NTA | N NANOFIBER |            |    |

| Formulation code | Entrapment Efficiency (%) |
|------------------|---------------------------|
| M1               | 60±0.12                   |
| M2               | 69±0.17                   |
| M3               | 78±0.12                   |
| M4               | 82±0.11                   |
| M5               | 95±0.04                   |
| PM               | 66±0.09                   |

# **Characterization of Macitentan Nanofibers:**

**Optical Microscopy:** The optical microscope (OP) magnifies an image by sending a beam of light through the object. The condenser lens focuses the light on the sample, and the objective lenses(10X, 40X, 2000X) magnify the beam, which contains the image; to the project or lens so the observer can view the image. Not many optical micrographs of nanofibers have been encountered in the open literature; however, this technique can give information about the overview of the nanofibers. An example is shown in **Fig. 1**.



FIG. 1: OPTICALMICROGRAPH: MACITENTANNANOFIBERS100X

# **FTIR Studies:**



FIG. 2: FTIR SPECTRA OF MACITENTAN

| Sr. no. | Functional group | Wave no.(cm <sup>-1</sup> ) |
|---------|------------------|-----------------------------|
| 1       | -OHstretch       | 3389                        |
| 2       | -C=O Stretch     | 1661                        |
| 3       | -C=Cstretch      | 1621                        |
| 4       | -CN Stretch      | 1076, 1026                  |



FIG. 3: FTIR SPECTRA OF MACITENTAN WITH PVP, SOYBEAN PC POLYMER COMPATIBILITY

SEM Analysis of Amphiphilic NFs and Templates: Fig. 4 shows the representative SEM images. The isolated and milled Macitentan powder consisted of large irregular particles with a particle size ranging from some tenths of micrometers to several hundred micrometers Fig. 4A. We discovered that the addition of Macitentan and soybean PC to the ES carrier polymer PVP had no impact on the efficiency of an ES process or the generation of NFs. The ES solutions containing Macitentan, soybean PC and PVP generated continuous elongated NFs with a smooth surface and uniform diameter **Fig. 4B**. The topography of the nanofibrous solid templates exhibited a nonwoven and loosely packed platform with randomly oriented individual NFs. The existing amphiphilic nanofibrous templates had exterior pores with sizes ranging from a few micrometers to ten micrometers.



FIG. 4: SEM MICROGRAPHS OF THE AMPHIPHILIC ELECTROSPUN NFS, WHICH CONSTITUTED AS A SOLID TEMPLATE FOR THE SELF-ASSEMBLED LIPOSOMES (B), AND AN ISOLATED AND MILLED MACITENTAN POWDER (A) 200 M (A) AND 2.0 M SCALE BARS (B)

International Journal of Pharmaceutical Sciences and Research

The amphiphilic NFs in our investigation had a figure diameter of 392 66 nm (n = 100) as assessed on the SEM micrographs Fig. 4. Individual NFs had diameters ranging from 197 nm to 534 nm. The average fiber diameter of the corresponding amphiphilic NFs (without Macitentan) ranged from 580nm to 1250nm. The size of the NFs can be tailored by varying the content of PC in the NFs, The average diameter of NFs made entirely from PVP was 910 110 nm, and as the NFs' PC content increased. particle diameter the average significantly reduced to 580 90 nm at 33.3% w/w PC. However, as the PC content was increased to 50% (w/w), the average diameter of NFs was significantly increased to 1010±110nm. The presence of PC, as a zwitterionic surfactant, changes the surface tension and viscosity of the PVP solution, thus affecting the morphology and diameter of the NFs. It is well known that PVP is a good carrier polymer for ES to generate NFs. PC generates electrostatic, hydrophobic interactions with PVP when administered to PVP solutions. The shape of a PVP chain and PVP-PVP molecular interactions are modified by these molecular-level interactions, which reduce entanglements and viscosity.

*In-vitro* **Drug Release:** The cumulative dissolution profiles of Macitentan loaded in the amphiphilic Electrospun NFs formulation M5 are shown in **Table 3** and **Fig. 5**.

| Time in (Hr) | % Drug Release of M5 |
|--------------|----------------------|
| 0            | 0                    |
| 1            | $8.74 \pm 1.23$      |
| 2            | $15.17 \pm 1.45$     |
| 3            | $20.24 \pm 1.12$     |
| 4            | $39.17 \pm 1.20$     |
| 5            | $58.14 \pm 1.53$     |
| 6            | $78.19 \pm 1.60$     |
| 12           | 82.19± 1.13          |
| 18           | $90.20 \pm 1.08$     |
| 24           | $95.17 \pm 1.90$     |
| 48           | 98.58± 1.65          |

More than 50% of Macitentan released within the first 2 h, approximately 80% released within the next 2 h, and the rest of the active agent (100%) released within 30 h. The initial burst release of the drug-loaded amphiphilic nanofibers could be attributed to the surface or near-surface distribution

of Macitentan in the nanofibers. This results in swelling of the nanofibrous template. Only evaluating the dissolve assessment of the current amphiphilic nanofibrous templates loaded with the active ingredient is the purpose of our dissolution investigation.



FIG. 5: THE *IN-VITRO* DISSOLUTION PROFILES OF MACITENTAN -LOADED AMPHIPHILIC ELECTRO-SPUN NFS FORMULATION M5

CONCLUSION: In the present research work bionanofibers were successfully developed by using the electros pining Method. SEM and FTIR etc investigated chemical structure, morphology, thermal stability of bio-nano-fibers. FTIR measurements show no interaction in between drug and polymers. In SEM study concluded that PVP is a good carrier polymer for ES to generate NFs. After drug loading, the surface area and roughness of nanofibers were decreased. The in-vitro activity showed a controlled release pattern of the drug from bionanofibers. Thus, the present investigation directs the delivery of drug through nanofibers at the targeted site.

**ACKNOWLEDGMENT:** The author is thankful to the management of Bhagwant University, Ajmer, for providing facilities during this and to Dr. K. Saravanan for his valuable suggestion during the work.

**CONFLICTS OF INTEREST:** The authors declare that there is not any conflict of interest.

#### **REFERENCE:**

- 1. Qasim SB, Zafar MS, Najeeb S, Khurshid Z, Shah AH, Husain S and Rehman IU: Electrospining of chitosanbased solutions for tissue engineering and regenerative medicine. Int J Mol Sci 2018; 19: 407.
- 2. Malabadi RB, Kolkar KP and Chalannavar K: Natural plant gum exudates and mucilage: pharmaceutical updates.

International Journal of Innovation Scientific Research and Review 2021; 3(10): 1897-912.

- Lan X, Wang H, Bai J, Miao X, Lin Q, Zheng J, Ding S, Li X and Tang Y: Multidrug-loaded electrospun micro/nanofibrous membranes: Fabrication strategies, release behaviors and applications in regenerative medicine. Journal of Controlled Release 2021; 330: 1264-87.
- Zamani R, Aval SF, Pilehvar SY, Nejati KK and Zarghami N: Recent advances in cell electrospining of natural and synthetic nanofibers for regenerative medicine. Drug Res 2018; 68: 425–435.
- 5. Zhang X, Xie L, Wang X, Shao Z and Kong B: Electrospinning super-assembly of ultrathin fibers from single-to multi-Taylor cone sites. Applied Materials Today 2021; 29: 101272.
- Deshmukh S, Kathiresan M and Kulandainathan MA: A review on biopolymer-derived electrospun nanofibers for biomedical and antiviral applications. Biomaterials Science 2022; 10(16): 4424-42.
- Díaz-Arca A, Ros-Tárraga P, Tomé MJ, De Aza AH, Meseguer-Olmo L, Mazón P and De Aza PN: Micro-/nano-structured ceramic scaffolds that mimic natural cancellous bone. Materials 2021; 14(6): 1439.
- Lodhi MK, Deen KM, Greenlee-Wacker MC and Haider W: Additively manufactured 316L stainless steel with improved corrosion resistance and biological response for biomedical applications. Add Manufac 2019; 27: 8-19.
- Oyatogun GM, Imasogie BI, Soboyejo WO, Abere VD, Oyatogun AO and Popoola AP: Investigation of the effects of laser micro-texturing on the cellular response of silicon surfaces. Ife Journal of Technology 2019; 26(1): 74-9.
- Agrahari V and Agrahari V: Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. Drug Discovery Today 2018; 23(5): 974-91.
- Jiang L, Jiang Y, Stiadle J, Wang X, Wang L, Thibeault S L and Turng LS: *Electrospun nanofibrous* thermoplastic polyurethane/poly(glycerol sebacate) hybrid scaffolds for vocal fold tissue engineering applications. Mater Sci Eng C 2019; 94: 740–749.
- Campiglio C, Marcolin C, Draghi L. Electrospun ECM macromolecules as biomimetic scaffold for regenerative medicine: Challenges for preserving conformation and bioactivity. AIMS J 2017; 4: 638–669.
- 13. Liu KS, Kao CW, Tseng YY, Chen SK, Lin YT, Lu CJ and Liu SJ: Assessment of antimicrobial agents, analgesics and epidermal growth factors-embedded anti-adhesive poly (lactic-co-glycolic acid) nanofibrous membranes: *Invitro* and *in-vivo* studies. International Journal of Nanomedicine 2021; 16: 4471.
- 14. Ghafoor B, Aleem A, Ali MN and Mir M: Review of the fabrication techniques and applications of polymeric

electrospun nanofibers for drug delivery systems. Journal of Drug Delivery Science and Technology 2018; 48: 82-7.

- 15. Bootdee K and Nithitanakul M: Poly (d, l-lactide-coglycolide) nanospheres within composite poly (vinyl alcohol)/aloe veraelectrospunnanofiber as a novel wound dressing for controlled release of drug. International Journal of Polymeric Materials and Polymeric Biomaterials 2021; 70(4): 223-30.
- Vieira S, Vial S, Reis RL and Oliveira JM: Nanoparticles for bone tissue engineering. Biotechnology Progress 2017; 33(3): 590-611.
- 17. Liu Y, Chen X, Yu DG, Liu H, Liu Y and Liu P: Electrospun PVP-core/PHBV-shell fibers to eliminate tailing off for an improved sustained release of curcumin. Molecular Pharmaceutics 2021; 18(11): 4170-8.
- Sadeghi A, Moztarzadeh F and Aghazadeh MJ: Investigating the effect of chitosan on hydrophilicity and bioactivity of conductive electrospun composite scaffold for neural tissue engineering. Int J Biol Macromol 2019; 121: 625–632.
- Venugopal E, Rajeswaran N, Sahanand KS, Bhattacharyya A and Rajendran S: *In-vitro* evaluation of phytochemical loaded electrospun gelatin nanofibers for application in bone and cartilage tissue engineering. Biomed Mater 2018; 14: 015004.
- Ding Y, Li W, Zhang F, Liu Z, Zanjanizadeh E N, Liu D and Santos HA: Electrospun fibrous architectures for drug delivery, tissue engineering and cancer therapy. Adv Funct Mater 2019; 29: 1802-1832.
- 21. Kishan AP and Cosgriff-Hernandez EM: Recent advancements in electrospinning design for tissue engineering applications: A review. Journal of Biomedical Materials Research Part A 2017; 105(10): 2892-905.
- 22. Torabi H and Ramazani Saadat Abadi A: Property investigation of poly (ethylene co-vinyl acetate)/poly (l-lactic acid)/organo clay nanocomposites. Journal of Polymers and the Environment 2019; 27: 2886-94.
- 23. Kurokawa N, Endo F, Maeda T and Hotta A: Electrospinning and surface modification methods for functionalized cell scaffolds. In Nanostructures for Novel Therapy 2017: 201-225.
- 24. Ye K, Liu D, Kuang H, Cai J, Chen W, Sun B, Xia L, Fang B, Morsi Y and Mo X: Three-dimensional electrospunnanofibrous scaffolds displaying bone morphogenetic protein-2-derived peptides for the promotion of osteogenic differentiation of stem cells and bone regeneration. J Colloid Interface Sci 2019; 534: 625– 636.
- Martin V and Bettencourt A: Bone regeneration: Biomaterials as local delivery systems with improved osteoinductive properties. Materials Science and Engineering C 2018; 82: 363-71.

#### How to cite this article:

Kharde SN and Saravanan K: Fabrication and characterization of drug loaded bionanofibers as a platform for drug delivery. Int J Pharm Sci & Res 2023; 14(8): 4015-20. doi: 10.13040/JJPSR.0975-8232.14(8).4015-20.

All © 2023 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to Android OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)